... of our lead clinical program SB-728-T, an autologous T-cell therapy designed to provide a functional cure for HIV/AIDS. Using our Zinc Finger Nuclease or ZFN technology, we can specifically disrupt the gene in coding CCR5, a required co-receptor for ...
http://seekingalpha.com/article/1569952-sangamo-biosciences-inc-sgmo-ceo-discusses-q2-2013-results-earnings-call-transcript?source=feed
http://seekingalpha.com/article/1569952-sangamo-biosciences-inc-sgmo-ceo-discusses-q2-2013-results-earnings-call-transcript?source=feed
No comments:
Post a Comment